Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to 0.78.

  • Iovance Biotherapeutics' Equity Ratio changed N/A to 0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.78, marking a year-over-year change of. This contributed to the annual value of 0.78 for FY2024, which is 415.57% up from last year.
  • Iovance Biotherapeutics' Equity Ratio amounted to 0.78 in Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Equity Ratio peaked at 0.81 during Q1 2023, and registered a low of 0.75 during Q4 2023.
  • Its 3-year average for Equity Ratio is 0.78, with a median of 0.78 in 2024.
  • Data for Iovance Biotherapeutics' Equity Ratio shows a peak YoY increase of 415.57% (in 2024) and a maximum YoY decrease of 331.2% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Equity Ratio stood at 0.75 in 2023, then rose by 4.16% to 0.78 in 2024, then dropped by 0.54% to 0.78 in 2025.
  • Its last three reported values are 0.78 in Q3 2025, 0.77 for Q2 2025, and 0.79 during Q1 2025.